The Motif Logo was generated from an N-Terminal AcetylScan® LC-MS/MS experiment using 839 nonredundant tryptic peptides derived from mouse liver, brain, and embryo tissues immunoprecipitated with PTMScan® N-Terminal Acetyl Motif Immunoaffinity Beads. The logo represents the relative frequency of amino acids in each position starting from the N-terminal residue of each peptide within this data set.Learn more about how we get our images
Cells are lysed in a urea-containing buffer, cellular proteins are digested by proteases, and the resulting peptides are purified by reversed-phase, solid-phase extraction. Peptides are then subjected to immunoaffinity purification using a PTMScan® Motif antibody conjugated to protein A agarose beads. Unbound peptides are removed through washing, and the captured PTM-containing peptides are eluted with dilute acid. Reversed-phase purification is performed on microtips to desalt and separate peptides from antibody prior to concentrating the enriched peptides for LC-MS/MS analysis. CST recommends the use of PTMScan® IAP Buffer #9993 included in the kit. A detailed protocol and Limited Use License allowing the use of the patented PTMScan® method is included with the kit.
Antibody beads supplied in IAP buffer containing 50% glycerol. Store at -20°C. Do not aliquot the antibody.
PTMScan® Technology employs a proprietary methodology from Cell Signaling Technology (CST) for peptide enrichment by immunoprecipitation using a specific bead-conjugated antibody in conjunction with liquid chromatography (LC) tandem mass spectrometry (MS/MS) for quantitative profiling of post-translational modification (PTM) sites in cellular proteins. These include phosphorylation (PhosphoScan®), ubiquitination (UbiScan®), acetylation (AcetylScan®), and methylation (MethylScan®), among others. PTMScan® Technology enables researchers to isolate, identify, and quantitate large numbers of post-translationally modified cellular peptides with a high degree of specificity and sensitivity, providing a global overview of PTMs in cell and tissue samples without preconceived biases about where these modified sites occur (1). For more information on PTMScan® Proteomics Services, please visit www.cellsignal.com/services/index.html
Various forms of N-terminal protein processing exist in eukaryotes that target the starting methionine amino acid. One such modification is acetylation of the N-terminal methionine accepted from acetyl-CoA. This is mediated by N-terminal acetyltransferases (Nats) and has been found to be present on a wide variety of proteins estimated from 50 to more than 80% of proteins in some cases. There are six identified Nats that are well conserved from yeast to humans (1). This widely observed modification has been implicated in a variety of protein processes from translation regulation, stability, folding, localization, transcriptional control, and protein protein interactions. It also plays a role in Histone tail modifications (2,3,4,5).
AcetylScan is a trademark of Cell Signaling Technology, Inc. Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. MethylScan is a trademark of Cell Signaling Technology, Inc. PTMScan is a trademark of Cell Signaling Technology, Inc. UbiScan is a trademark of Cell Signaling Technology, Inc. Use of Cell Signaling Technology (CST) Motif Antibodies within certain methods (e.g., U.S. Patents No. 7,198,896 and 7,300,753) may require a license from CST. For information regarding academic licensing terms please have your technology transfer office contact CST Legal Department at CST_ip@cellsignal.com. For information regarding commercial licensing terms please contact CST Pharma Services Department at email@example.com.